Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2025)
Candel Therapeutics (CADL) reported Non-Current Deffered Revenue of $89000.0 for Q4 2025, down 17.59% sequentially from $108000.0 in Q3 2023.
Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 5 years of Non-Current Deffered Revenue data on file, last reported at $89000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $89000.0; the trailing twelve-month figure through Dec 2025 stood at $89000.0 (changed N/A YoY), and the FY2025 full-year result was $89000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue fell to $89000.0 in Q4 2025, from $108000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $894000.0 in Q4 2021 to a low of $63000.0 in Q2 2021.
- A 4-year average of $263000.0 and a median of $126000.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue soared 41.46% in 2021 and tumbled 83.89% in 2022, its largest moves.
- Tracing CADL's Non-Current Deffered Revenue over 4 years: stood at $894000.0 in 2021, then plunged by 83.89% to $144000.0 in 2022, then dropped by 25.0% to $108000.0 in 2023, then declined by 17.59% to $89000.0 in 2025.
- Business Quant data shows CADL's Non-Current Deffered Revenue at $89000.0 in Q4 2025, $108000.0 in Q3 2023, and $120000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89,000.00 |
| Sep 30, 2023 | 108,000.00 |
| Jun 30, 2023 | 120,000.00 |
| Mar 31, 2023 | 132,000.00 |
| Dec 31, 2022 | 144,000.00 |
| Dec 31, 2021 | 894,000.00 |
| Sep 30, 2021 | 554,000.00 |
| Jun 30, 2021 | 63,000.00 |
| Dec 31, 2020 | 632,000.00 |